Stay updated on Brigatinib Post Next-Gen ALK Inhibitors Clinical Trial

Sign up to get notified when there's something new on the Brigatinib Post Next-Gen ALK Inhibitors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Brigatinib Post Next-Gen ALK Inhibitors Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    The site updated to revision v3.4.2, and the previous notice about government funding and operating status was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T14:08:32.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A banner about a government funding lapse and operational status was added, with links to cc.nih.gov and opm.gov for updates, and the page version was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:14:23.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Show glossary option is now visible and can be expanded for definitions. Footer/metadata labels updated to include 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and the revision version 'v3.4.0'.
    Difference
    0.2%
    Check dated 2026-01-28T05:45:39.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    - Revision updated from v3.3.3 to v3.3.4.
    Difference
    0.1%
    Check dated 2026-01-14T01:22:43.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    A unified Locations section now lists Colorado, North Carolina, Tennessee, and Texas, replacing the previous separate location headings.
    Difference
    0.5%
    Check dated 2025-12-23T21:20:20.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    Updated the PubMed publications description and added a revision label; core study data, endpoints, and eligibility criteria remain unchanged.
    Difference
    0.1%
    Check dated 2025-11-25T13:59:35.000Z thumbnail image

Stay in the know with updates to Brigatinib Post Next-Gen ALK Inhibitors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Brigatinib Post Next-Gen ALK Inhibitors Clinical Trial page.